We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.
- Authors
Eichhorn, Florian; Kriegsmann, Mark; Klotz, Laura V.; Kriegsmann, Katharina; Muley, Thomas; Zgorzelski, Christiane; Christopoulos, Petros; Winter, Hauke; Eichhorn, Martin E.; Goto, Akiteru
- Abstract
Simple Summary: The analysis of prognostic biomarkers (e.g., PD-L1) helps to define treatment for lung cancer patients. To date, these markers have only been examined in metastatic or inoperable situations. We analyzed the PD-L1 expression-levels of tumors from 277 lung cancer patients that underwent curative intent surgery. PD-L1 was identified as a prognostic factor, depending on histologic subtype. The programmed death-ligand 1 (PD-L1) plays a crucial role in immunomodulatory treatment concepts for end-stage non-small cell lung cancer (NSCLC). To date, its prognostic significance in patients with curative surgical treatment but regional nodal metastases, reflecting tumor spread beyond the primary site, is unclear. We evaluated the prognostic impact of PD-L1 expression in a surgical cohort of 277 consecutive patients with pN1 NSCLC on a tissue microarray. Patients with PD-L1 staining (clone SP263) on >1% of tumor cells were defined as PD-L1 positive. Tumor-specific survival (TSS) of the entire cohort was 64% at five years. Low tumor stage (p < 0.0001) and adjuvant therapy (p = 0.036) were identified as independent positive prognostic factors in multivariate analysis for TSS. PD-L1 negative patients had a significantly better survival following adjuvant chemotherapy than PD-L1 positive patients. The benefit of adjuvant therapy diminished in patients with PD-L1 expression in more than 10% of tumor cells. Stratification towards histologic subtype identified PD-L1 as a significant positive predictive factor for TSS after adjuvant therapy in patients with adenocarcinoma, but not squamous cell carcinoma. Routine PD-L1 assessment in curative intent treatment may help to identify patients with a better prognosis. Further research is needed to elucidate the predictive value of PD-L1 in an adjuvant setting.
- Subjects
LUNG cancer prognosis; LUNG cancer treatment; TISSUE arrays; STATISTICAL significance; PREDICTIVE tests; MULTIVARIATE analysis; IMMUNOHISTOCHEMISTRY; LOG-rank test; RETROSPECTIVE studies; REGRESSION analysis; GENE expression; TUMOR classification; SURVIVAL analysis (Biometry); DESCRIPTIVE statistics; CHI-squared test; MEMBRANE proteins; CELL lines; COMBINED modality therapy; DATA analysis software; LONGITUDINAL method; IMMUNOTHERAPY; PROPORTIONAL hazards models
- Publication
Cancers, 2021, Vol 13, Issue 9, p2046
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13092046